Pharmacokinetic evaluation of frovatriptan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1449-1458

  Negro, Andrea ^a   Lionetto, Luana ^b   Casolla, Barbara ^b   Lala, Noemi ^a   Simmaco, Maurizio ^b   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cluster headache; Frovatriptan; Menstrual migraine; Migraine; Pharmacodynamics; Pharmacokinetics; Triptans

Indexed keywords

ALMOTRIPTAN; FROVATRIPTAN; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

BLOOD PRESSURE; CHEST TIGHTNESS; CLUSTER HEADACHE; CORONARY ARTERY SPASM; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FATIGUE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NONHUMAN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SIDE EFFECT; TACHYCARDIA; THROAT TIGHTNESS; XEROSTOMIA;

CARBAZOLES; CLUSTER HEADACHE; DRUG EVALUATION; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 80054717425     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.622265     Document Type: Review

References (77)

1. Cady R, Schreiber C. Sumatriptan: update and review. Expert Opin Pharmacother 2006;7:1503-14 (Pubitemid 44173211)
2. Buchan P, Keywood C, Wade A, Ward C. Clinical pharmacokinetics of frovatriptan. Headache 2002;42(Suppl 2):S54-62 (Pubitemid 34568918)
3. Lipton RB. Disability assessment as a basis for stratified care. Cephalalgia 1998;18(Suppl 22):40-3
4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
5. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58 (Pubitemid 36609333)
6. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations. How to match patients and products. CNS Drugs 2003;17:431-47 (Pubitemid 36560705)
7. Lucas C. Strategies to improve migraine treatment results. Drugs 2006;66(Suppl 3):9-16 (Pubitemid 44833583)
8. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70:1505-18
9. Belvis R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Patent CNS Drug Discov 2009;4:70-81
10. Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005;9:206-12 (Pubitemid 40873175)
11. Helfand M, Peterson K. Drug class review: triptans: final report update 4. Portland (OR): Oregon Health & Science University 2009;1-264
12. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003;2:123-7
13. Loder E. Triptan therapy in migraine. N Engl J Med 2010;363:63-70
14. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001;28:30-41
15. Gentile G, Borro M, Lala N, et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5
16. Gentile G, Missori S, Borro M, et al. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010;11:151-6
17. Napier C, Stewart M, Melrose H, et al. Characterization of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368:259-68 (Pubitemid 29117148)
18. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-88 (Pubitemid 36417768)
19. McHarg AD, Napier CM, Stewart M, et al. The functional activity of eletriptan and other 5-HT1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptor. Headache 1999;39:369-70
20. Jahnichen S, Radtke OA, Pertz HH. Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol 2004;370:54-63 (Pubitemid 39141521)
21. Comer MB. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache 2002;42(Suppl 2):S47-53 (Pubitemid 34568917)
22. Van den Broek RWM, Bhalla P, MaassenVanDenBrink A, et al. Characterization of sumatriptan induced contractions in human isolated blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ hybridization. Cephalalgia 2002;22:83-93 (Pubitemid 34494127)
23. Graul A, Leson P, Castaner J. SB-209509/VML-251. Drugs Future 1997;22:725-8
24. Ferrari MD. Migraine. Lancet 1998;351:1043-51 (Pubitemid 28155822)
25. Eglen RM, Jasper JR, Chang DJ, et al. The 5-HT7 receptor: orphan found. Trends Pharmacol Sci 1997;18:104-7
26. Tfelt Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87 (Pubitemid 32039386)
27. Parsons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT (1B 1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998;32:220-4 (Pubitemid 28350641)
28. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112:135-40 (Pubitemid 34142545)
29. Elkind AH, Satin LZ, Nila A, et al. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache 2004;44:403-10 (Pubitemid 38685547)
30. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol 2004;44:1158-65 (Pubitemid 39202460)
31. Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61:313-20 (Pubitemid 36648734)
32. Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002;42(Suppl 2):S74-83 (Pubitemid 34568920)
33. Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache 2002;42:41-8 (Pubitemid 34136610)
34. MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30 (Pubitemid 28312075)
35. Parsons AA, Parker SG, Raval P, et al. Comparison of the cardiovascular effects of the novel 5-HT1B/1D receptor agonist SB 209509 (VML 251) and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-41 (Pubitemid 27527386)
36. Parsons AA, Valocik R, Koster P, et al. Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. J Cardiovasc Pharmacol 1998;32:995-1000 (Pubitemid 28563924)
37. Carel I, Ghaleh B, Edouard A, et al. Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol 2001;132:1071-83 (Pubitemid 32238913)
38. Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(Suppl 2):S84-92 (Pubitemid 34568921)
39. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005;30:521-32 (Pubitemid 43960978)
40. Tfelt-Hansen P. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain 2011;12:275-80
41. Tfelt-Hansen P. Parenteral versus oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 2007;8:273-6 (Pubitemid 350214724)
42. Spierings EL, Keywood C. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med 2009;10:633-8
43. Wallasch T-M. Frovatriptan in the practice of office-based neurologists and pain therapists: the ALADIN study. Adv Ther 2010;27:56-62
44. Pfaffenrath V, Spierings ELH. Acute treatment of migraine attacks: frovatriptan 2.5mg an effective and economical alternative. Nervenheilkunde 2004;23:545-8 (Pubitemid 39573072)
45. Mathew NT, Kailasam J, Gentry P, et al. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000;40:464-5 (Pubitemid 30421878)
46. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31 (Pubitemid 34136608)
47. Pascual J, Diener HC, Massiou H. Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain 2006;7:27-33 (Pubitemid 43337098)
48. Hutchison J, Pfaffenrath V, Geraud G. A randomized, placebo-controlled, parallel-group trial of frovatriptan and sumatriptan for a single acute migraine attack [letter]. Eur J Neurol 2007;14(Suppl 1):144
49. Tullo V, Allais G, Ferrari MD, et al. Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 2010;31(Suppl 1):S51-4
50. Savi L, Omboni S, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011;12:219-26
51. Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011;12:361-8
52. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
53. Guidotti M, Ravasio R. Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world setting. Clin Drug Investig 2009;29:693-702
54. Tfelt-hansen P. When to use frovatriptan in migraine? J Headache Pain 2011;12:393-4
55. Fierro B, Omboni S, Bertolini M, et al. When to use frovatriptan? A reply. J Headache Pain 2011;12:395-6
56. Saxena PR, Tfelt-hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-hansen P, Welch KMA. editors. The Headaches. 3rd edition. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 469-503
57. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9 (Pubitemid 46184209)
58. Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-9 (Pubitemid 23221829)
59. Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27(Suppl 2):S193-7 (Pubitemid 44390141)
60. Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20:1019-26 (Pubitemid 44912709)
61. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27:414-21 (Pubitemid 46632603)
62. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037-49 (Pubitemid 47057222)
63. MacGregor EA, Keywood C. Frovatriptan is effective in menstrually associated migraine. Cephalalgia 2000;20:345-8
64. Brandes JL, Poole AC, Kallela M, et al. Short-term frovatriptan for the prevention of difficult to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-48
65. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9 (Pubitemid 38971124)
66. Pageler L, Katsarava Z, Lampl C, et al. Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. Headache 2011;51:129-34
67. Lipton RB, Micieli G, Russell D, et al. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia 1995;15:452-62
68. Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. Headache 2011;51:369-74
69. Lanteri-Minet M. Clinical use of triptans in the management of migraine. CNS Drugs 2006;20(Suppl 1):12-23
70. Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr 2009;67:559-69
71. Silberstein SD. Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. Headache 2002;42(Suppl 2):S45-6 (Pubitemid 34568916)
72. Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007;8:3029-33 (Pubitemid 350285016)
73. Balbisi EA. Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract 2004;58:695-705 (Pubitemid 39144585)
74. Buchan P, Wade A, Ward C, et al. Frovatriptan: a review of drug-drug interactions. Headache 2002;42(Suppl2):S63-73 (Pubitemid 34568919)
75. Balbisi EA. Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag 2006;2:303-8 (Pubitemid 44349505)
76. Allais G, Bussone G, De Lorenzo C, et al. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci 2005;26(Suppl 2):S125-9 (Pubitemid 40796496)
77. Steiner TJ, Birbeck GL, Jensen R, et al. The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain 2011;12:273-4